Adrenal Gland Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chromogranin A (CgA), which is a major protein in adrenal chromaffin cells and adrenergic neurons, is a clinically relevant endocrine and neuroendocrine tumor marker including pheochromocytomas, neuroblastomas, and related neurogenic tumors.
|
31682468 |
2020 |
Adrenal Gland Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma.
|
31027285 |
2019 |
Adrenal Gland Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Positive chromogranin A staining of the tumor cells confirmed a diagnosis of pheochromocytoma.
|
30078826 |
2018 |
Adrenal Gland Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Radioimmunoassay of chromogranin A and free metanephrines in diagnosis of pheochromocytoma.
|
28948824 |
2017 |
Adrenal Gland Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the immunostaining of CgA in the tumor cells showed peculiar dot-like staining located corresponding to Golgi complex in the perinuclear area, rather than the diffuse cytoplasmic staining usually observed in epinephrine- or norepinephrine-producing functional pheochromocytomas and paragangliomas.
|
27743246 |
2017 |
Adrenal Gland Pheochromocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A retrospective study of SDHB and SDHD NIH patients' cohort, which included 41 patients with SDHB mutation-related PHEO/sPGL and 18 patients with either SDHD or SDHB mutation-related head and neck PGL (HNPGL) with both CgA and NMN measured at the time of diagnosis at NIH.
|
24467715 |
2014 |
Adrenal Gland Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We can conclude that plasma CGA concentration as determined by radioimmunometric assay (which is simple without the necessity of special laboratory equipment) is an effective marker of pheochromocytoma with association to malignity and tumor mass.
|
18271679 |
2008 |
Adrenal Gland Pheochromocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we therefore compared tumour and plasma levels of CGA in patients with phaeochromocytoma associated with the two syndromes.
|
18046660 |
2007 |
Adrenal Gland Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have recently validated several assays for the measurement of peptides derived from chromogranin A (CgA) and secretogranin II (SgII) in order to determine whether these secreted neuroendocrine products could provide useful, complementary markers for the diagnosis and prognosis of PHEOs.
|
17102122 |
2006 |
Adrenal Gland Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also screened members of families with MEN-2 or von Hippel-Lindau disease for pheochromocytoma by measuring plasma and urine catecholamines and plasma chromogranin A and by performing abdominal ultrasonography, CT and MRI, and metaiodobenzylguanidine scintigraphy.
|
8105382 |
1993 |
Adrenal Gland Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The change in chromogranin A plasma concentration after pheochromocytoma resection best fit a two-compartment model, with an initial rapid half-life time of 16 minutes, followed by a longer half-life time of 520 minutes.
|
2189303 |
1990 |
Adrenal Gland Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
An mRNA of approximately 2.3Kb was detected with the cDNA probes in human cell lines from MTC and lung cancers that were shown to produce CgA and in human pheochromocytoma and bovine adrenal medulla tissue.
|
3718511 |
1986 |